GSK ups respiratory pipeline with $1.4bn Aiolos Bio buy
GSK adds long-acting antibody A1O-001 to its respiratory biologics portfolio through the acquisition of Aiolos Bio.
GSK adds long-acting antibody A1O-001 to its respiratory biologics portfolio through the acquisition of Aiolos Bio.
The deal will see GlaxoSmithKline (GSK) pay Aiolos – a clinical-stage firm founded in 2023 focused on patients with inflammatory and respiratory conditions – $1 billion upfront. Additionally, there is the potential for the firm to receive up to $400 million depending on milestones.
Through the acquisition, GSK gains access to Aiolos’ AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb). The drug candidate is about to enter Phase II clinical development for the treatment of individuals with asthma, with the possibility for additional indications including nasal polyps and chronic rhinosinusitis.